Drug Approval | August 27, 2024
Merck receives EC approval for Winrevair for treatment of PAH
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
ZenBio is a highly regarded science-focused company specializing in biospecimens and related services with scientific expertise
Roche confirms that its cobas MPXV test, as well as the LightMix research use only kits, detect the latest mpox virus variants
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
The partnership marks a significant milestone in integrating digital health education into medical curricula
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Subscribe To Our Newsletter & Stay Updated
